Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTACDR1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS 3	JUN 06	KOREAPAT updated with 41,000 documents
NEWS 4	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS 5	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS 6	JUN 25	CA/CAplus and USPAT databases updated with IPC reclassification data
NEWS 7	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS 8	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS 9	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS 10	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS 11	JUL 28	CA/CAplus patent coverage enhanced
NEWS 12	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS 13	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS 14	JUL 28	STN Viewer performance improved
NEWS 15	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS 16	AUG 13	CA/CAplus enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS 17	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS 18	AUG 15	CAplus currency for Korean patents enhanced
NEWS 19	AUG 27	CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information
NEWS 20	SEP 18	Support for STN Express, Versions 6.01 and earlier, to be discontinued
NEWS 21	SEP 25	CA/CAplus current-awareness alert options enhanced to accommodate supplemental CAS indexing of exemplified prophetic substances
NEWS 22	SEP 26	WPIDS, WPINDEX, and WPIX coverage of Chinese and and Korean patents enhanced
NEWS 23	SEP 29	IFICLS enhanced with new super search field
NEWS 24	SEP 29	EMBASE and EMBAL enhanced with new search and display fields
NEWS 25	SEP 30	CAS patent coverage enhanced to include exemplified prophetic substances identified in new Japanese-language patents
NEWS 26	OCT 07	EPFULL enhanced with full implementation of EPC2000
NEWS 27	OCT 07	Multiple databases enhanced for more flexible patent number searching

```
 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:23:04 ON 14 OCT 2008

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 15:23:11 ON 14 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   12 OCT 2008  HIGHEST RN 1060442-20-7
DICTIONARY FILE UPDATES:  12 OCT 2008  HIGHEST RN 1060442-20-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\11664190s8.str
```



```
chain nodes :
7  8  9  10  11  12  13  14  15
ring nodes :
1  2  3  4  5  6
chain bonds :
1-7  4-10  7-8  7-9  10-11  10-14  10-15  11-12  12-13
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6
exact/norm bonds :
1-2  1-6  1-7  2-3  3-4  4-5  5-6  7-8  7-9  10-11  11-12  12-13
exact bonds :
4-10  10-14  10-15


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  9:CLASS  10:CLASS
 11:CLASS  12:CLASS  13:CLASS  14:CLASS  15:CLASS



L1      STRUCTURE UPLOADED

=> s l1 sss sam
SAMPLE SEARCH INITIATED 15:23:26 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      421 TO ITERATE

100.0% PROCESSED      421 ITERATIONS                                50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         7189 TO     9651
PROJECTED ANSWERS:             736 TO     1664

L2           50 SEA SSS SAM L1

=> d scan

L2   50 ANSWERS   REGISTRY  COPYRIGHT 2008 ACS on STN
IN   2-Furancarboxamide, N-(2-methyl-3-phenyl-2-propen-1-yl)-N-[[1-(2-
```

naphthalenylsulfonyl)-4-piperidinyl]methyl]-
MF C31 H32 N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=>
Uploading C:\Program Files\STNEXP\Queries\11664190s9.str



chain nodes :
7 8 9 10 11 12 13 14 15 16
ring nodes :
1 2 3 4 5 6
chain bonds :
1-7 4-10 7-8 7-9 10-11 10-14 10-15 11-12 11-16 12-13
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
1-2 1-6 1-7 2-3 3-4 4-5 5-6 7-8 7-9 10-11 11-12 12-13
exact bonds :
4-10 10-14 10-15 11-16

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS

```
L3      STRUCTURE UPLOADED

=> s l3 sss sam
SAMPLE SEARCH INITIATED 15:24:47 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      421 TO ITERATE

100.0% PROCESSED      421 ITERATIONS                                30 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         7189 TO     9651
PROJECTED ANSWERS:             272 TO      928

L4           30 SEA SSS SAM L3

=> s l3 sss full
FULL SEARCH INITIATED 15:24:58 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     8643 TO ITERATE

100.0% PROCESSED     8643 ITERATIONS                              645 ANSWERS
SEARCH TIME: 00.00.01

L5          645 SEA SSS FUL L3

=> file caplus
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                 179.28     179.49

FILE 'CAPLUS' ENTERED AT 15:25:03 ON 14 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 14 Oct 2008  VOL 149 ISS 16
FILE LAST UPDATED: 12 Oct 2008  (20081012/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l5
L6          63 L5

=> s l5 and NMDA
```

```
           63 L5
        30199 NMDA
            2 NMDAS
        30199 NMDA
                (NMDA OR NMDAS)
L7          4 L5 AND NMDA

=> d ibib abs hitstr 1-4

L7   ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:        2006:1093266  CAPLUS
DOCUMENT NUMBER:         145:432223
TITLE:                   Method of treating schizophrenia prodrome
INVENTOR(S):             Woods, Scott W.
PATENT ASSIGNEE(S):      Yale University, USA
SOURCE:                  PCT Int. Appl., 64pp.
                         CODEN: PIXXD2
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
     WO 2006110724        A2    20061019    WO 2006-US13444        20060411
     WO 2006110724        A3    20070322
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
             KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
             MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
             SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
             VN, YU, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
             CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
             GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM
     AU 2006235400        A1    20061019    AU 2006-235400         20060411
     CA 2602626           A1    20061019    CA 2006-2602626        20060411
     EP 1871165           A2    20080102    EP 2006-740849         20060411
         R:  AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,
             BA, HR, MK, YU
     JP 2008535864        T     20080904    JP 2008-505637         20060411
PRIORITY APPLN. INFO.:                      US 2005-670600P     P  20050411
                                            WO 2006-US13444     W  20060411
OTHER SOURCE(S):         MARPAT 145:432223
AB   The present invention relates to a method of treating schizophrenia
     prodrome in human subjects using a NMDA glycine site agonist, a
     glycine transporter-1 inhibitor or mixts. thereof, optionally in
     combination with a pharmaceutically acceptable additive, carrier or
     excipient.
IT   852029-09-5
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (method of treating schizophrenia prodrome with NMDA glycine
        agonist and glycine transporter-1 inhibitor)
RN   852029-09-5  CAPLUS
CN   Benzamide, 2-chloro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]-
       (CA INDEX NAME)
```



L7 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:964146 CAPLUS
DOCUMENT NUMBER: 138:39187
TITLE: Preparation of piperidinecarboxylates and related compounds as NMDA NR2B receptor antagonists for the treatment or prevention of migraine.
INVENTOR(S): Allen, Christopher; Koblan, Ken S.; Sleeth, Timothy
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 185 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002100352	A2	20021219	WO 2002-US21069	20020607
WO 2002100352	A3	20030327		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2449249	A1	20021219	CA 2002-2449249	20020607
AU 2002346050	A1	20021223	AU 2002-346050	20020607
EP 1399160	A2	20040324	EP 2002-744807	20020607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004537526	T	20041216	JP 2003-503178	20020607
US 20040204341	A1	20041014	US 2003-479923	20031205
PRIORITY APPLN. INFO.:			US 2001-297672P P	20010612
			WO 2002-US21069 W	20020607

AB A method for treating or preventing migraines comprises administration of an NR2B receptor antagonist (no data). The invention also encompasses the combination of an NR2B antagonist with a cyclooxygenase-2 selective inhibitor, a calcitonin gene-related peptide receptor (CGRP) ligand, a leukotriene receptor antagonist, or a 5HT1B/1D agonist for the treatment or prevention of migraines. Thus, 4-hydroxybenzoic acid, 1-hydroxybenzotriazole hydrate, benzyl 4-(aminomethyl)piperidine-1-carboxylate (preparation given), and Et3N in DMF were treated with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride and the mixture allowed to stir at room temperature for 18 h to give
4-[(4-hydroxybenzoylamino)methyl]piperidine-1-carboxylic acid benzyl

ester.

IT 471250-27-8P 471250-28-9P 471250-29-0P
471250-30-3P 471250-31-4P 471250-33-6P
471250-34-7P 471250-35-8P 471250-36-9P
471250-37-0P 471250-38-1P 471250-39-2P
471250-40-5P 471250-41-6P 471250-42-7P
471250-45-0P 471250-46-1P 478552-66-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of piperidinecarboxylates and related compds. as NR2B receptor antagonists for the treatment or prevention of migraine)

RN 471250-27-8 CAPLUS
CN 4-Pyridinecarboxamide, N-[[1-[(2-phenylethyl)sulfonyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 471250-28-9 CAPLUS
CN Benzamide, N-[[1-[[2-(4-fluorophenyl)ethyl]sulfonyl]-4-piperidinyl]methyl]-4-hydroxy- (CA INDEX NAME)



RN 471250-29-0 CAPLUS
CN 4-Pyridinecarboxamide, N-[[1-[[2-(4-methylphenyl)ethyl]sulfonyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 471250-30-3 CAPLUS
CN 1H-Benzimidazole-6-carboxamide, N-[[1-[(2-phenylethyl)sulfonyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 471250-31-4 CAPLUS
CN 4-Pyrimidinecarboxamide, N-[[1-[(2-phenylethyl)sulfonyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 471250-33-6 CAPLUS
CN 2-Pyrazinecarboxamide, N-[[1-[(2-phenylethyl)sulfonyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 471250-34-7 CAPLUS
CN 2-Pyrazinecarboxamide, 3-amino-N-[[1-[(2-phenylethyl)sulfonyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 471250-35-8 CAPLUS
CN 5-Pyrimidinecarboxamide, N-[[1-[(2-phenylethyl)sulfonyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 471250-36-9 CAPLUS
CN 4-Pyrimidinecarboxamide, N-[[1-[[2-(4-methylphenyl)ethyl]sulfonyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 471250-37-0 CAPLUS
CN 9H-Purine-6-carboxamide, N-[[1-[(2-phenylethyl)sulfonyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 471250-38-1 CAPLUS
CN Benzamide, N-[[1-[[2-(4-chlorophenyl)ethyl]sulfonyl]-4-piperidinyl]methyl]-4-hydroxy- (CA INDEX NAME)



RN 471250-39-2 CAPLUS

CN Benzamide, N-[[1-[[2-(2-fluorophenyl)ethyl]sulfonyl]-4-piperidinyl]methyl]-4-hydroxy- (CA INDEX NAME)



RN 471250-40-5 CAPLUS
CN 3-Pyridinecarboxamide, 1,6-dihydro-6-oxo-N-[[1-[(2-phenylethyl)sulfonyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 471250-41-6 CAPLUS
CN Benzamide, 4-hydroxy-N-[[1-[(2-phenylethyl)sulfonyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 471250-42-7 CAPLUS
CN 4-Pyridazinecarboxamide, N-[[1-[(2-phenylethyl)sulfonyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 471250-45-0 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-amino-N-[[1-[(2-phenylethyl)sulfonyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 471250-46-1 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-amino-N-[[1-[[2-(4-methylphenyl)ethyl]sulfonyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 478552-66-8 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-amino-N-[[1-[(2-phenylethyl)sulfonyl]-4-piperidinyl]methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

IT 455267-19-3P 455267-23-9P 455267-41-1P
455267-42-2P 471254-11-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of piperidinecarboxylates and related compds. as NR2B receptor antagonists for the treatment or prevention of migraine)

RN 455267-19-3 CAPLUS
CN Carbamic acid, [[1-[[(1E)-2-phenylethenyl]sulfonyl]-4-piperidinyl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 455267-23-9 CAPLUS
CN Carbamic acid, [[1-[[2-(4-fluorophenyl)ethyl]sulfonyl]-4-piperidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 455267-41-1 CAPLUS
CN Carbamic acid, [[(3-exo)-8-[[(1E)-2-phenylethenyl]sulfonyl]-8-azabicyclo[3.2.1]oct-3-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 455267-42-2 CAPLUS
CN Carbamic acid, [[(3-exo)-8-[(2-phenylethyl)sulfonyl]-8-azabicyclo[3.2.1]oct-3-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 471254-11-2 CAPLUS
CN Carbamic acid, [5-[[[[1-[(2-phenylethyl)sulfonyl]-4-piperidinyl]methyl]amino]carbonyl]-2-pyrimidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L7 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:793427 CAPLUS
DOCUMENT NUMBER: 137:310932
TITLE: Preparation of N-substituted nonaryl heterocyclyl amides as NMDA/NR2B antagonists for relieving pain
INVENTOR(S): Liverton, Nigel J.; Butcher, John W.; McIntyre, Charles J.; Claiborne, Christopher F.; Claremon, David A.; McCauley, James A.; Romano, Joseph J.; Thompson, Wayne; Munson, Peter M.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 270 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002080928	A1	20021017	WO 2002-US10269	20020402
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2443108	A1	20021017	CA 2002-2443108	20020402
AU 2002338334	A1	20021021	AU 2002-338334	20020402
AU 2002338334	B2	20080814		
US 20030119811	A1	20030626	US 2002-114685	20020402
US 7259157	B2	20070821		
EP 1390034	A1	20040225	EP 2002-763896	20020402
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2005511478	T	20050428	JP 2002-578967	20020402
PRIORITY APPLN. INFO.:			US 2001-281166P P	20010403
			WO 2002-US10269 W	20020402

OTHER SOURCE(S): MARPAT 137:310932
GI



I



II

AB The title compds. [I; NonAr = nonarom. 5-7 membered containing heteroatoms; A = (un)substituted Ph, pyrrolyl, imidazolyl, etc.; B = aryl(CH2)0-3(CH2)0-2CO, heteroaryl(CH2)1-3O(CH2)0-2CO, etc.; X = H, OH, F, etc.] which are effective as NMDA NR2B antagonists useful for relieving pain, were prepared E.g., a 2-step synthesis of II, starting with 4-aminomethylpiperidine, was given. The compds. I exhibit IC50's of less than 50 μM in the FLIPR and binding assays, and thus they have been found to exhibit biol. activity as NMDA NR2B antagonists.

IT 471250-27-8P 471250-28-9P 471250-29-0P
471250-30-3P 471250-31-4P 471250-32-5P
471250-33-6P 471250-34-7P 471250-35-8P
471250-36-9P 471250-37-0P 471250-38-1P
471250-39-2P 471250-40-5P 471250-41-6P
471250-42-7P 471250-45-0P 471250-46-1P
471250-89-2P 471250-92-7P 471251-27-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-substituted nonaryl heterocyclyl amides as NMDA /NR2B antagonists for relieving pain)

RN 471250-27-8 CAPLUS

CN 4-Pyridinecarboxamide, N-[[1-[(2-phenylethyl)sulfonyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 471250-28-9 CAPLUS

CN Benzamide, N-[[1-[[2-(4-fluorophenyl)ethyl]sulfonyl]-4-piperidinyl]methyl]-4-hydroxy- (CA INDEX NAME)



RN 471250-29-0 CAPLUS
CN 4-Pyridinecarboxamide, N-[[1-[[2-(4-methylphenyl)ethyl]sulfonyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 471250-30-3 CAPLUS
CN 1H-Benzimidazole-6-carboxamide, N-[[1-[(2-phenylethyl)sulfonyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 471250-31-4 CAPLUS
CN 4-Pyrimidinecarboxamide, N-[[1-[(2-phenylethyl)sulfonyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 471250-32-5 CAPLUS
CN 1H-Imidazole-5-carboxamide, 1-methyl-N-[[1-[(2-phenylethyl)sulfonyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 471250-33-6 CAPLUS
CN 2-Pyrazinecarboxamide, N-[[1-[(2-phenylethyl)sulfonyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 471250-34-7 CAPLUS
CN 2-Pyrazinecarboxamide, 3-amino-N-[[1-[(2-phenylethyl)sulfonyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 471250-35-8 CAPLUS
CN 5-Pyrimidinecarboxamide, N-[[1-[(2-phenylethyl)sulfonyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 471250-36-9 CAPLUS
CN 4-Pyrimidinecarboxamide, N-[[1-[[2-(4-methylphenyl)ethyl]sulfonyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 471250-37-0 CAPLUS
CN 9H-Purine-6-carboxamide, N-[[1-[(2-phenylethyl)sulfonyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 471250-38-1 CAPLUS
CN Benzamide, N-[[1-[[2-(4-chlorophenyl)ethyl]sulfonyl]-4-piperidinyl]methyl]-4-hydroxy- (CA INDEX NAME)



RN 471250-39-2 CAPLUS
CN Benzamide, N-[[1-[[2-(2-fluorophenyl)ethyl]sulfonyl]-4-piperidinyl]methyl]-4-hydroxy- (CA INDEX NAME)



RN 471250-40-5 CAPLUS
CN 3-Pyridinecarboxamide, 1,6-dihydro-6-oxo-N-[[1-[(2-phenylethyl)sulfonyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 471250-41-6 CAPLUS
CN Benzamide, 4-hydroxy-N-[[1-[(2-phenylethyl)sulfonyl]-4-piperidinyl]methyl]-

(CA INDEX NAME)



RN 471250-42-7 CAPLUS
CN 4-Pyridazinecarboxamide, N-[[1-[(2-phenylethyl)sulfonyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 471250-45-0 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-amino-N-[[1-[(2-phenylethyl)sulfonyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 471250-46-1 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-amino-N-[[1-[[2-(4-methylphenyl)ethyl]sulfonyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 471250-89-2 CAPLUS
CN 1H-Indole-5-carboxamide, N-[[1-[(2-phenylethyl)sulfonyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 471250-92-7 CAPLUS
CN 1H-Indole-6-carboxamide, N-[[1-[(2-phenylethyl)sulfonyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 471251-27-1 CAPLUS
CN Benzamide, 4-hydroxy-N-[[1-[(2,4,6-trimethylphenyl)sulfonyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



IT 455267-19-3P 455267-23-9P 471254-11-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-substituted nonaryl heterocyclyl amides as NMDA /NR2B antagonists for relieving pain)

RN 455267-19-3 CAPLUS
CN Carbamic acid, [[1-[[(1E)-2-phenylethenyl]sulfonyl]-4-piperidinyl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 455267-23-9 CAPLUS

CN Carbamic acid, [[1-[[2-(4-fluorophenyl)ethyl]sulfonyl]-4-piperidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 471254-11-2 CAPLUS
CN Carbamic acid, [5-[[[[1-[(2-phenylethyl)sulfonyl]-4-piperidinyl]methyl]amino]carbonyl]-2-pyrimidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:676010 CAPLUS
DOCUMENT NUMBER: 137:216875
TITLE: Preparation of N-acyl-4-(heterocyclylaminomethyl)piperidines as NMDA/NR2B antagonists
INVENTOR(S): Claiborne, Christopher F.; Butcher, John W.; Claremon, David A.; Libby, Brian E.; Liverton, Nigel J.; Munson, Peter M.; Nguyen, Kevin T.; Phillips, Brian; Thompson, Wayne; McCauley, John A.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 208 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002068409	A1	20020906	WO 2002-US5226	20020220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2438895	A1	20020906	CA 2002-2438895	20020220
AU 2002252053	A1	20020912	AU 2002-252053	20020220
AU 2002252053	B2	20060914		

US 20020165241	A1	20021107	US 2002-79452		20020220
US 7053089	B2	20060530			
EE 200300403	A	20031215	EE 2003-403		20020220
EP 1379520	A1	20040114	EP 2002-721105		20020220
EP 1379520	B1	20060426			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
HU 2003003258	A2	20040128	HU 2003-3258		20020220
HU 2003003258	A3	20040628			
BR 2002007526	A	20040309	BR 2002-7526		20020220
CN 1503793	A	20040609	CN 2002-808713		20020220
JP 2004524314	T	20040812	JP 2002-567923		20020220
NZ 527365	A	20050826	NZ 2002-527365		20020220
AT 324371	T	20060515	AT 2002-721105		20020220
PT 1379520	T	20060831	PT 2002-721105		20020220
ES 2261658	T3	20061116	ES 2002-721105		20020220
US 20040209889	A1	20041021	US 2003-470561		20030729
US 7217716	B2	20070515			
ZA 2003006159	A	20040705	ZA 2003-6159		20030808
BG 108113	A	20050430	BG 2003-108113		20030819
NO 2003003732	A	20031022	NO 2003-3732		20030822
MX 2003PA07621	A	20031204	MX 2003-PA7621		20030822
IN 2003CN01316	A	20051125	IN 2003-CN1316		20030822
KR 849839	B1	20080801	KR 2003-711079		20030822
PRIORITY APPLN. INFO.:			US 2001-271100P	P	20010223
			WO 2002-US5226	W	20020220

OTHER SOURCE(S): MARPAT 137:216875

AB BQ1(X)ANHQ2 [Q1 = 5-7 membered N-containing nonarom. ring, azabicyclooctyl; Q2 = 5-6 membered (substituted) heteroaryl ring; A = alkylene; B = Ar(CH2)0-3O2C, Ar(CH2)0-3SO2, etc.; Ar = (substituted) aryl, heteroaryl; X = H, OH, F, alkyl, alkoxy, NH2, O], were prepared Thus, 1-[(benzyloxy)carbonyl]-4-piperidinecarboxylic acid, 4-aminopyridine, EDC, and HOAt were kept 4 h in DMF to give the amide, which was reduced with BH3.THF to give benzyl 4-[(4-pyridylamino)methyl]-1-piperidinecarboxylate. Title compds. showed IC50's of <50 μM for inhibition of NR1A/2B NMDA receptor activation.

IT 455267-19-3P 455267-23-9P 455267-41-1P
455267-42-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-acyl-4-(heterocyclylaminomethyl)piperidines as NMDA/NR2B antagonists)

RN 455267-19-3 CAPLUS

CN Carbamic acid, [[1-[[(1E)-2-phenylethenyl]sulfonyl]-4-piperidinyl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 455267-23-9 CAPLUS

CN Carbamic acid, [[1-[[2-(4-fluorophenyl)ethyl]sulfonyl]-4-piperidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 455267-41-1 CAPLUS
CN Carbamic acid, [[(3-exo)-8-[[(1E)-2-phenylethenyl]sulfonyl]-8-azabicyclo[3.2.1]oct-3-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 455267-42-2 CAPLUS
CN Carbamic acid, [[(3-exo)-8-[(2-phenylethyl)sulfonyl]-8-azabicyclo[3.2.1]oct-3-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s l5 and schizophrenia
63 L5
20172 SCHIZOPHRENIA
39 SCHIZOPHRENIAS
20176 SCHIZOPHRENIA

(SCHIZOPHRENIA OR SCHIZOPHRENIAS)
L8 12 L5 AND SCHIZOPHRENIA

=> d ibib abs hitstr 12

L8 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:676010 CAPLUS
DOCUMENT NUMBER: 137:216875
TITLE: Preparation of N-acyl-4-(heterocyclylaminomethyl)piperidines as NMDA/NR2B antagonists
INVENTOR(S): Claiborne, Christopher F.; Butcher, John W.; Claremon, David A.; Libby, Brian E.; Liverton, Nigel J.; Munson, Peter M.; Nguyen, Kevin T.; Phillips, Brian; Thompson, Wayne; McCauley, John A.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 208 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002068409	A1	20020906	WO 2002-US5226	20020220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2438895	A1	20020906	CA 2002-2438895	20020220
AU 2002252053	A1	20020912	AU 2002-252053	20020220
AU 2002252053	B2	20060914		
US 20020165241	A1	20021107	US 2002-79452	20020220
US 7053089	B2	20060530		
EE 200300403	A	20031215	EE 2003-403	20020220
EP 1379520	A1	20040114	EP 2002-721105	20020220
EP 1379520	B1	20060426		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 2003003258	A2	20040128	HU 2003-3258	20020220
HU 2003003258	A3	20040628		
BR 2002007526	A	20040309	BR 2002-7526	20020220
CN 1503793	A	20040609	CN 2002-808713	20020220
JP 2004524314	T	20040812	JP 2002-567923	20020220
NZ 527365	A	20050826	NZ 2002-527365	20020220
AT 324371	T	20060515	AT 2002-721105	20020220
PT 1379520	T	20060831	PT 2002-721105	20020220
ES 2261658	T3	20061116	ES 2002-721105	20020220
US 20040209889	A1	20041021	US 2003-470561	20030729
US 7217716	B2	20070515		
ZA 2003006159	A	20040705	ZA 2003-6159	20030808
BG 108113	A	20050430	BG 2003-108113	20030819
NO 2003003732	A	20031022	NO 2003-3732	20030822
MX 2003PA07621	A	20031204	MX 2003-PA7621	20030822
IN 2003CN01316	A	20051125	IN 2003-CN1316	20030822
KR 849839	B1	20080801	KR 2003-711079	20030822

PRIORITY APPLN. INFO.: US 2001-271100P P 20010223
WO 2002-US5226 W 20020220

OTHER SOURCE(S): MARPAT 137:216875

AB BQ1(X)ANHQ2 [Q1 = 5-7 membered N-containing nonarom. ring, azabicyclooctyl; Q2 = 5-6 membered (substituted) heteroaryl ring; A = alkylene; B = Ar(CH2)0-3O2C, Ar(CH2)0-3SO2, etc.; Ar = (substituted) aryl, heteroaryl; X = H, OH, F, alkyl, alkoxy, NH2, O], were prepared Thus, 1-[(benzyloxy)carbonyl]-4-piperidinecarboxylic acid, 4-aminopyridine, EDC, and HOAt were kept 4 h in DMF to give the amide, which was reduced with BH3.THF to give benzyl 4-[(4-pyridylamino)methyl]-1-piperidinecarboxylate. Title compds. showed IC50's of <50 μM for inhibition of NR1A/2B NMDA receptor activation.

IT 455267-19-3P 455267-23-9P 455267-41-1P
455267-42-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-acyl-4-(heterocyclylaminomethyl)piperidines as NMDA/NR2B antagonists)

RN 455267-19-3 CAPLUS

CN Carbamic acid, [[1-[[(1E)-2-phenylethenyl]sulfonyl]-4-piperidinyl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 455267-23-9 CAPLUS

CN Carbamic acid, [[1-[[2-(4-fluorophenyl)ethyl]sulfonyl]-4-piperidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 455267-41-1 CAPLUS

CN Carbamic acid, [[(3-exo)-8-[[(1E)-2-phenylethenyl]sulfonyl]-8-azabicyclo[3.2.1]oct-3-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



RN 455267-42-2 CAPLUS
CN Carbamic acid, [[(3-exo)-8-[(2-phenylethyl)sulfonyl]-8-azabicyclo[3.2.1]oct-3-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib abs hitstr 11

L8 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:793427 CAPLUS
DOCUMENT NUMBER: 137:310932
TITLE: Preparation of N-substituted nonaryl heterocyclyl amides as NMDA/NR2B antagonists for relieving pain
INVENTOR(S): Liverton, Nigel J.; Butcher, John W.; McIntyre, Charles J.; Claiborne, Christopher F.; Claremon, David A.; McCauley, James A.; Romano, Joseph J.; Thompson, Wayne; Munson, Peter M.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 270 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002080928	A1	20021017	WO 2002-US10269	20020402

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2443108	A1	20021017	CA 2002-2443108		20020402
AU 2002338334	A1	20021021	AU 2002-338334		20020402
AU 2002338334	B2	20080814			
US 20030119811	A1	20030626	US 2002-114685		20020402
US 7259157	B2	20070821			
EP 1390034	A1	20040225	EP 2002-763896		20020402
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2005511478	T	20050428	JP 2002-578967		20020402
PRIORITY APPLN. INFO.:			US 2001-281166P	P	20010403
			WO 2002-US10269	W	20020402

OTHER SOURCE(S): MARPAT 137:310932

GI



I



II

AB The title compds. [I; NonAr = nonarom. 5-7 membered containing heteroatoms; A = (un)substituted Ph, pyrrolyl, imidazolyl, etc.; B = aryl(CH2)0-3(CH2)0-2CO, heteroaryl(CH2)1-3O(CH2)0-2CO, etc.; X = H, OH, F, etc.] which are effective as NMDA NR2B antagonists useful for relieving pain, were prepared E.g., a 2-step synthesis of II, starting with 4-aminomethylpiperidine, was given. The compds. I exhibit IC50's of less than 50 μM in the FLIPR and binding assays, and thus they have been found to exhibit biol. activity as NMDA NR2B antagonists.

IT 471250-27-8P 471250-28-9P 471250-29-0P
471250-30-3P 471250-31-4P 471250-32-5P
471250-33-6P 471250-34-7P 471250-35-8P
471250-36-9P 471250-37-0P 471250-38-1P
471250-39-2P 471250-40-5P 471250-41-6P
471250-42-7P 471250-45-0P 471250-46-1P
471250-89-2P 471250-92-7P 471251-27-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-substituted nonaryl heterocyclyl amides as NMDA/NR2B antagonists for relieving pain)

RN 471250-27-8 CAPLUS
CN 4-Pyridinecarboxamide, N-[[1-[(2-phenylethyl)sulfonyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 471250-28-9 CAPLUS
CN Benzamide, N-[[1-[[2-(4-fluorophenyl)ethyl]sulfonyl]-4-piperidinyl]methyl]-4-hydroxy- (CA INDEX NAME)



RN 471250-29-0 CAPLUS
CN 4-Pyridinecarboxamide, N-[[1-[[2-(4-methylphenyl)ethyl]sulfonyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 471250-30-3 CAPLUS
CN 1H-Benzimidazole-6-carboxamide, N-[[1-[(2-phenylethyl)sulfonyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 471250-31-4 CAPLUS
CN 4-Pyrimidinecarboxamide, N-[[1-[(2-phenylethyl)sulfonyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 471250-32-5 CAPLUS
CN 1H-Imidazole-5-carboxamide, 1-methyl-N-[[1-[(2-phenylethyl)sulfonyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 471250-33-6 CAPLUS
CN 2-Pyrazinecarboxamide, N-[[1-[(2-phenylethyl)sulfonyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 471250-34-7 CAPLUS
CN 2-Pyrazinecarboxamide, 3-amino-N-[[1-[(2-phenylethyl)sulfonyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 471250-35-8 CAPLUS
CN 5-Pyrimidinecarboxamide, N-[[1-[(2-phenylethyl)sulfonyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 471250-36-9 CAPLUS
CN 4-Pyrimidinecarboxamide, N-[[1-[[2-(4-methylphenyl)ethyl]sulfonyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 471250-37-0 CAPLUS
CN 9H-Purine-6-carboxamide, N-[[1-[(2-phenylethyl)sulfonyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 471250-38-1 CAPLUS
CN Benzamide, N-[[1-[[2-(4-chlorophenyl)ethyl]sulfonyl]-4-piperidinyl]methyl]-4-hydroxy- (CA INDEX NAME)



RN 471250-39-2 CAPLUS

CN Benzamide, N-[[1-[[2-(2-fluorophenyl)ethyl]sulfonyl]-4-piperidinyl]methyl]-4-hydroxy- (CA INDEX NAME)



RN 471250-40-5 CAPLUS
CN 3-Pyridinecarboxamide, 1,6-dihydro-6-oxo-N-[[1-[(2-phenylethyl)sulfonyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 471250-41-6 CAPLUS
CN Benzamide, 4-hydroxy-N-[[1-[(2-phenylethyl)sulfonyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 471250-42-7 CAPLUS
CN 4-Pyridazinecarboxamide, N-[[1-[(2-phenylethyl)sulfonyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 471250-45-0 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-amino-N-[[1-[(2-phenylethyl)sulfonyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 471250-46-1 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-amino-N-[[1-[[2-(4-methylphenyl)ethyl]sulfonyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 471250-89-2 CAPLUS
CN 1H-Indole-5-carboxamide, N-[[1-[(2-phenylethyl)sulfonyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 471250-92-7 CAPLUS
CN 1H-Indole-6-carboxamide, N-[[1-[(2-phenylethyl)sulfonyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 471251-27-1 CAPLUS
CN Benzamide, 4-hydroxy-N-[[1-[(2,4,6-trimethylphenyl)sulfonyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



IT 455267-19-3P 455267-23-9P 471254-11-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-substituted nonaryl heterocyclyl amides as NMDA/NR2B antagonists for relieving pain)

RN 455267-19-3 CAPLUS
CN Carbamic acid, [[1-[[(1E)-2-phenylethenyl]sulfonyl]-4-piperidinyl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 455267-23-9 CAPLUS
CN Carbamic acid, [[1-[[2-(4-fluorophenyl)ethyl]sulfonyl]-4-piperidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 471254-11-2 CAPLUS
CN Carbamic acid, [5-[[[[1-[(2-phenylethyl)sulfonyl]-4-piperidinyl]methyl]amino]carbonyl]-2-pyrimidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib abs hitstr 10

L8 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:451128 CAPLUS
DOCUMENT NUMBER: 142:476263
TITLE: 4-Phenylpiperidine derivative glycine transporter inhibitors for the treatment of neurological and psychiatric disorders
INVENTOR(S): Lindsley, Craig W.; Wisnoski, David D.; Zhao, Zhijian
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 76 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005046601	A2	20050526	WO 2004-US37359		20041110
WO 2005046601	A3	20050818			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2004289290	A1	20050526	AU 2004-289290		20041110
CA 2544981	A1	20050526	CA 2004-2544981		20041110
EP 1684759	A2	20060802	EP 2004-810610		20041110
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS					
CN 1878551	A	20061213	CN 2004-80033295		20041110
JP 2007512251	T	20070517	JP 2006-539749		20041110
IN 2006DN01895	A	20070615	IN 2006-DN1895		20060407
US 20070105902	A1	20070510	US 2006-579261		20060511
PRIORITY APPLN. INFO.:			US 2003-519348P	P	20031112
			WO 2004-US37359	W	20041110

OTHER SOURCE(S): MARPAT 142:476263

AB The invention discloses 4-phenylpiperidine derivs. that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurol. and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction and diseases in which the glycine transporter GlyT1 is involved. Compound preparation is described.

IT 852029-09-5P 852029-10-8P 852029-11-9P
852029-12-0P 852029-13-1P 852029-14-2P
852029-15-3P 852029-16-4P 852029-17-5P
852029-18-6P 852029-19-7P 852029-20-0P
852029-21-1P 852029-22-2P 852029-23-3P
852029-24-4P 852029-25-5P 852029-26-6P
852029-27-7P 852029-28-8P 852029-29-9P
852029-30-2P 852029-31-3P 852029-32-4P
852029-33-5P 852029-35-7P 852029-36-8P
852029-37-9P 852029-38-0P 852029-39-1P
852029-40-4P 852029-49-3P 852029-53-9P
852029-54-0P 852029-55-1P 852029-56-2P
852029-63-1P 852029-64-2P 852029-65-3P
852029-66-4P 852029-67-5P 852029-68-6P
852029-69-7P 852029-73-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(phenylpiperidine derivative glycine transporter inhibitors for treatment of neurol. and psychiatric disorders)

RN 852029-09-5 CAPLUS
CN Benzamide, 2-chloro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-10-8 CAPLUS
CN Butanamide, N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-11-9 CAPLUS
CN Benzamide, 4-chloro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-12-0 CAPLUS
CN Benzamide, 2-fluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-13-1 CAPLUS
CN Benzamide, 2-methyl-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-14-2 CAPLUS
CN Cyclopropanecarboxamide, 2-phenyl-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]-, (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 852029-15-3 CAPLUS
CN Cyclohexanecarboxamide, N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-16-4 CAPLUS
CN Benzamide, 2,6-difluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-17-5 CAPLUS
CN Benzamide, N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 852029-18-6 CAPLUS
CN Benzamide, N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 852029-19-7 CAPLUS
CN 3-Pyridinecarboxamide, 2-chloro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-20-0 CAPLUS
CN Benzeneacetamide, 2-bromo-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-21-1 CAPLUS
CN Benzamide, 2,3-difluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-22-2 CAPLUS
CN Benzamide, 3-fluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 852029-23-3 CAPLUS
CN Benzamide, N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]-2-(trifluoromethoxy)- (CA INDEX NAME)



RN 852029-24-4 CAPLUS
CN Benzamide, 2-chloro-3,6-difluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-25-5 CAPLUS
CN Benzamide, 2-(difluoromethoxy)-N-[[4-phenyl-1-(propylsulfonyl)-4-

piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-26-6 CAPLUS
CN Benzamide, 2,5-dichloro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-27-7 CAPLUS
CN Benzamide, 2,6-dichloro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-28-8 CAPLUS
CN Benzamide, N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-29-9 CAPLUS
CN 3-Pyridinecarboxamide, 2-(methylthio)-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-30-2 CAPLUS
CN 3-Pyridinecarboxamide, 2,6-dichloro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-31-3 CAPLUS
CN Benzamide, 2-chloro-6-fluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-32-4 CAPLUS
CN Benzamide, 2-chloro-6-methyl-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-33-5 CAPLUS
CN Benzamide, 2-bromo-3-fluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-35-7 CAPLUS
CN Benzamide, 2-bromo-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-36-8 CAPLUS
CN Benzamide, 2-amino-6-fluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-37-9 CAPLUS
CN Benzamide, 2-amino-6-chloro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-38-0 CAPLUS
CN Benzamide, 2-amino-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 852029-39-1 CAPLUS
CN Benzamide, 2-iodo-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-40-4 CAPLUS
CN Benzamide, 2-fluoro-6-iodo-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-49-3 CAPLUS
CN Benzamide, 2-fluoro-6-hydroxy-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-53-9 CAPLUS
CN Benzamide, N-[[4-(4-fluorophenyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]-2-(trifluoromethoxy)- (CA INDEX NAME)



RN 852029-54-0 CAPLUS
CN Benzamide, 2-chloro-N-[[4-(4-fluorophenyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-55-1 CAPLUS
CN Benzamide, 2-amino-6-chloro-N-[[4-(4-fluorophenyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-56-2 CAPLUS
CN Benzamide, N-[[4-(4-fluorophenyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]-2-(methylthio)- (CA INDEX NAME)



RN 852029-63-1 CAPLUS
CN Benzamide, N-[[4-(3-fluorophenyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-64-2 CAPLUS
CN Benzamide, 2-chloro-N-[[4-(3-fluorophenyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-65-3 CAPLUS
CN Benzamide, 2,6-difluoro-N-[[4-(3-fluorophenyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-66-4 CAPLUS
CN Benzamide, 2-amino-6-chloro-N-[[4-(2-fluorophenyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-67-5 CAPLUS
CN Benzamide, 2-chloro-6-fluoro-N-[[4-(2-fluorophenyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-68-6 CAPLUS
CN Benzamide, N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]-2-[[(2,2,2-trifluoroethyl)amino]methyl]- (CA INDEX NAME)



RN 852029-69-7 CAPLUS
CN Benzamide, 2-[[[2-(diethylamino)ethyl]amino]methyl]-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-73-3 CAPLUS
CN 3-Pyridinecarboxamide, 4-iodo-2-(methylamino)-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



=> s l5 and glycine
63 L5
170626 GLYCINE
2668 GLYCINES
171897 GLYCINE
(GLYCINE OR GLYCINES)
L9 10 L5 AND GLYCINE

=> d ibib abs hitstr 10

L9 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:451128 CAPLUS
DOCUMENT NUMBER: 142:476263
TITLE: 4-Phenylpiperidine derivative glycine transporter inhibitors for the treatment of neurological and psychiatric disorders
INVENTOR(S): Lindsley, Craig W.; Wisnoski, David D.; Zhao, Zhijian
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 76 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005046601	A2	20050526	WO 2004-US37359	20041110
WO 2005046601	A3	20050818		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2004289290	A1	20050526	AU 2004-289290		20041110
CA 2544981	A1	20050526	CA 2004-2544981		20041110
EP 1684759	A2	20060802	EP 2004-810610		20041110
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS					
CN 1878551	A	20061213	CN 2004-80033295		20041110
JP 2007512251	T	20070517	JP 2006-539749		20041110
IN 2006DN01895	A	20070615	IN 2006-DN1895		20060407
US 20070105902	A1	20070510	US 2006-579261		20060511
PRIORITY APPLN. INFO.:			US 2003-519348P	P	20031112
			WO 2004-US37359	W	20041110

OTHER SOURCE(S): MARPAT 142:476263

AB The invention discloses 4-phenylpiperidine derivs. that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurol. and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction and diseases in which the glycine transporter GlyT1 is involved. Compound preparation is described.

IT 852029-09-5P 852029-10-8P 852029-11-9P
852029-12-0P 852029-13-1P 852029-14-2P
852029-15-3P 852029-16-4P 852029-17-5P
852029-18-6P 852029-19-7P 852029-20-0P
852029-21-1P 852029-22-2P 852029-23-3P
852029-24-4P 852029-25-5P 852029-26-6P
852029-27-7P 852029-28-8P 852029-29-9P
852029-30-2P 852029-31-3P 852029-32-4P
852029-33-5P 852029-35-7P 852029-36-8P
852029-37-9P 852029-38-0P 852029-39-1P
852029-40-4P 852029-49-3P 852029-53-9P
852029-54-0P 852029-55-1P 852029-56-2P
852029-63-1P 852029-64-2P 852029-65-3P
852029-66-4P 852029-67-5P 852029-68-6P
852029-69-7P 852029-73-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(phenylpiperidine derivative glycine transporter inhibitors for treatment of neurol. and psychiatric disorders)

RN 852029-09-5 CAPLUS

CN Benzamide, 2-chloro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-10-8 CAPLUS
CN Butanamide, N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-11-9 CAPLUS
CN Benzamide, 4-chloro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-12-0 CAPLUS
CN Benzamide, 2-fluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-13-1 CAPLUS
CN Benzamide, 2-methyl-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-14-2 CAPLUS
CN Cyclopropanecarboxamide, 2-phenyl-N-[[4-phenyl-1-(propylsulfonyl)-4-

piperidinyl]methyl]-, (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 852029-15-3 CAPLUS
CN Cyclohexanecarboxamide, N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-16-4 CAPLUS
CN Benzamide, 2,6-difluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-17-5 CAPLUS
CN Benzamide, N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 852029-18-6 CAPLUS
CN Benzamide, N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 852029-19-7 CAPLUS
CN 3-Pyridinecarboxamide, 2-chloro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-20-0 CAPLUS
CN Benzeneacetamide, 2-bromo-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-21-1 CAPLUS
CN Benzamide, 2,3-difluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-22-2 CAPLUS
CN Benzamide, 3-fluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 852029-23-3 CAPLUS
CN Benzamide, N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]-2-(trifluoromethoxy)- (CA INDEX NAME)



RN 852029-24-4 CAPLUS
CN Benzamide, 2-chloro-3,6-difluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-25-5 CAPLUS
CN Benzamide, 2-(difluoromethoxy)-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-26-6 CAPLUS
CN Benzamide, 2,5-dichloro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-27-7 CAPLUS
CN Benzamide, 2,6-dichloro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-28-8 CAPLUS
CN Benzamide, N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-29-9 CAPLUS
CN 3-Pyridinecarboxamide, 2-(methylthio)-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-30-2 CAPLUS
CN 3-Pyridinecarboxamide, 2,6-dichloro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-31-3 CAPLUS
CN Benzamide, 2-chloro-6-fluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-32-4 CAPLUS
CN Benzamide, 2-chloro-6-methyl-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-33-5 CAPLUS
CN Benzamide, 2-bromo-3-fluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-35-7 CAPLUS
CN Benzamide, 2-bromo-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-36-8 CAPLUS
CN Benzamide, 2-amino-6-fluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-37-9 CAPLUS
CN Benzamide, 2-amino-6-chloro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-38-0 CAPLUS
CN Benzamide, 2-amino-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 852029-39-1 CAPLUS
CN Benzamide, 2-iodo-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-40-4 CAPLUS
CN Benzamide, 2-fluoro-6-iodo-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-49-3 CAPLUS
CN Benzamide, 2-fluoro-6-hydroxy-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-53-9 CAPLUS
CN Benzamide, N-[[4-(4-fluorophenyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]-2-(trifluoromethoxy)- (CA INDEX NAME)



RN 852029-54-0 CAPLUS
CN Benzamide, 2-chloro-N-[[4-(4-fluorophenyl)-1-(propylsulfonyl)-4-

piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-55-1 CAPLUS
CN Benzamide, 2-amino-6-chloro-N-[[4-(4-fluorophenyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-56-2 CAPLUS
CN Benzamide, N-[[4-(4-fluorophenyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]-2-(methylthio)- (CA INDEX NAME)



RN 852029-63-1 CAPLUS
CN Benzamide, N-[[4-(3-fluorophenyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-64-2 CAPLUS
CN Benzamide, 2-chloro-N-[[4-(3-fluorophenyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-65-3 CAPLUS
CN Benzamide, 2,6-difluoro-N-[[4-(3-fluorophenyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-66-4 CAPLUS
CN Benzamide, 2-amino-6-chloro-N-[[4-(2-fluorophenyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-67-5 CAPLUS
CN Benzamide, 2-chloro-6-fluoro-N-[[4-(2-fluorophenyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-68-6 CAPLUS
CN Benzamide, N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]-2-[[(2,2,2-trifluoroethyl)amino]methyl]- (CA INDEX NAME)



RN 852029-69-7 CAPLUS
CN Benzamide, 2-[[[2-(diethylamino)ethyl]amino]methyl]-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-73-3 CAPLUS
CN 3-Pyridinecarboxamide, 4-iodo-2-(methylamino)-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



```
=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      55.72     235.21

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -6.40      -6.40

STN INTERNATIONAL LOGOFF AT 15:31:57 ON 14 OCT 2008
```